Sponsors





















Exhibition

Blood Donor Biobank (BRK), Definiens, dichrom, FGK Clinical Research, ForBiMed, LGC Limited, Miltenyi Biotec, tebu-bio and many more.

Exhibition space and sponsoring options available at: www.m4.de/mbc

Media Partners







enterprise europe network

One-2-One Partnering

Create your profile and meet leading scientists and business experts during the conference.



Bilateral meetings will take place November 25th, 10:50 - 17:30 and November 26th, 9:10 - 16:30. Last chance to book meetings is November 23rd.

The partnering is only for registered participants of the $4^{\rm th}$ Munich Biomarker Conference and free of charge.

Conference Homepage

www.m4.de/mbc

Venue

Hilton Munich Park Hotel Am Tucherpark 7, D-80538 Munich www.hilton.de/muenchenpark

Registration

To register, please go to: www.m4.de/mbc

Industry rate

395 € (until October 10th, 2014) 460 € (after October 10th, 2014) 270 € (one-day-ticket)

Academic rate

245 € (until October 10th, 2014) 290 € (after October 10th, 2014) 170 € (one-day-ticket)

All prices are subject to an additional 19% VAT.
All participants are cordially invited to the dinner reception in the Munich Residence on day 1.

Contact

Bio^M Biotech Cluster Develoment GmbH Am Klopferspitz 19a, D-82152 Martinsried

Phone +49 (0) 89 89 96 79 0 Fax +49 (0) 89 89 96 79 79 Email info@bio-m.org Web www.bio-m.org

The m⁴ leading-edge cluster is sponsored by





Bavarian Ministry of Economic Affairs and Media, Energy and Technology








4th Munich Biomarker Conference

Programme

November 25th - 26th, 2014 Hilton Munich Park Hotel



www.m4.de/mbc



Welcome to the 4th Munich Biomarker Conference

For the fourth year in a row, the Munich Biomarker Conference connects the biotech and pharma industry with scientists and physicians to discuss the most recent trends of biomarker research. The past Munich Biomarker Conferences each attracted a diverse audience of about 250 experts, laying ground for interdisciplinary exchange and collaborations.

Poster Session



The Munich Biomarker Conference offers extensive networking opportunities, for example the poster session. High-level posters encourage in-depth discussions of research findings and concepts.

Exhibition



As an essential part of the event, the exhibition is integrated into the conference space and provides a lively meeting point. A wide variety of technologies and services for biomarker research is presented.

Partnering



The one-2-one partnering is free of charge for all registered participants. Personal meetings, e.g. with potential collaborators, technology suppliers or licensing partners can be set up in advance.

Evening Event

On conference day 1, the State of Bavaria will hold a festive dinner reception in the historical Munich Residence.

Tuesday, November 25th

CMI in hemodialysis patients

Ludwig Deml, Lophius Biosciences, Regensburg, GER

9:00	Welcome Horst Domdey, Bio ^M Biotech Cluster Development GmbH	14:20	RT-qPCR analysis of laser capture micro-dissected material from CD31 stained FFPE tissue sections Sabine Lohmann, Roche Diagnostics GmbH, Penzberg, GER
	Systems Approaches	14:40	Dynamic peptide microarrays for activity-based
09:20	From genes to pathways and networks - systems approaches to personalized medicine		biomarker discovery Rob Ruijtenbeek, PamGene Int., 's-Hertogenbosch, NL
	Rudi Balling, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, LUX	15:00	Sponsored Talk Advancements in antibody-based proteomic analysis in
10:00	Mass spectrometry-based draft of the human proteome Hannes Hahne, Technische Universität München and		biomarker discovery Bryon Ricketts, Cell Signaling Technology, Leiden, NL
	OmicScouts GmbH, Freising, GER	15:20	Coffee Break and Exhibition
10:30	Coffee Break and Exhibition		
	Biomarker Discovery		Development Strategies
	biolitaikei Discovery	15:50	Best practises in companion diagnostic collaborations
11:10	DNA-methylation- and autoantibody-biomarker		Jens Dhein, Abbott GmbH & Co. KG, Wiesbaden, GER
	development strategies for minimal invasive diagnostics Andreas Weinhäusl, Austrian Institute of Technology - Molecular Diagnostics, Vienna, AT	16:20	Shaping diagnostic practice to drug development moving beyond biomarkers Chris Chamberlain, UCB, Slough, UK
11:30	Discovery and evaluation of biomarkers for bladder cancer Stefan Miller, PolyQuant GmbH, Bad Abbach, GER	16:50	Panel Discussion Collaborations in biomarker development –
11:50	Exploiting cancer metabolism to achieve biomarkers for diagnosis and personalized treatment Adelbert Roscher, Biocrates AG, Innsbruck and Ludwig-Maximilians-Universität, Munich, GER		where are the niches for biotech SMEs? Chair: Claire Skentelbery, Council of European Bioregions Chris Chamberlain, UCB Pharma Jens Dhein, Abbott Robert Löwe, Genewake
12:10	RNA-DNA divergence rate predicts clinical outcome of triple negative breast cancer BenoitThouvenot, Genclis SAS, Vandoeuvre-lès-Nancy, FR	17:35	Closing Remarks Horst Domdey, Bio ^M Biotech Cluster Development GmbH
12:30	Lunch Break and Exhibition		
13:00	Poster Session		
	Technology Highlights	17:40	Start at 7:00 p.m., in the
14:00	Suitability of T-Track CMV to assess the functionality of		'Max-Joseph-Saal' of the

Munich Residence

Wednesday, November 26th

Zentrum München, Neuherberg, GER

12:40

09:00	Opening Horst Domdey, Bio ^M Biotech Cluster Development GmbH	13:00	Lunch Break and Exhibition
	Horst Bolliday, Blo Blotoon Glaster Bevelopment ambit	13:30	Poster Session
	Big data for precision medicine		
09:10	Personalized medicine: the future is now Erwin Böttinger, The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine Mount Sinai, New York, USA	14:00	A novel immune-based approach for monitoring cancer patients Henry Hepburne-Scott, Serametrix, Carlsbad, USA
09:50	Virtualisation of drug testing in oncology by predictive systems biology modelling Bodo Lange, AlacrisTheranostics GmbH, Berlin, GER	14:20	Molecular profiling of single circulating tumor cells Bernhard Polzer, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, GER
10:10	From metabiobanks to translational research platforms: integrating Big Data through CRIP tools Christina Schröder, Fraunhofer IZI-BB, Potsdam, GER	14:40	Heregulin as predictive biomarker in the HERALD study of patritumab + erlotinib in advanced NSCLC Joachim von Pawel, Asklepios-Fachkliniken München-
10:30	Coffee Break and Exhibition		Gauting, GER
11:10	Biomarkers for early detection and prevention Biomarkers in lung cancer early detection: primetime for	15:00	Methylated free-circulating HPP1 DNA has a prognostic and predictive role for CRC patients Andreas Herbst, Ludwig-Maximilians-Universität, Munich, GER
	clinical trials? John Field, Chair of Molecular Oncology, University of Liverpool, UK	15:20	Outlook tba
11:40	Metabolic biomarkers for the differential diagnosis of pancreatic cancer vs. chronic pancreatitis Regina Reszka, Metanomics Health GmbH, Berlin, GER	16:00	Closing Remarks Horst Domdey, Bio ^M Biotech Cluster Development GmbH
12:00	Blood circulating micro RNAs with potential clinical utility for the management of bone disease Matthias Hackl, TAmiRNA GmbH, Vienna, AT		
12:20	Metabolic signature in pre-diabetes allows life style or medical intervention in risk individuals Jerzy Adamski, Genome Analysis Center, Helmholtz		